ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
Search
Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative
Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Data Privacy Statement
This privacy statement of Boehringer Ingelheim International GmbH (hereafter "Boehringer Ingelheim") describes what personal data are collected by this website and how these data are processed.
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim Fremont Employee Benefit Highlights
BI Fremont offers an excellent, competitive benefit package that takes care of you & your family. Our benefits package reflects BI’s culture & core values.
Corporate Profile
Corporate Profile
Combating The Rise of Heartworm Disease in Dogs | Boehringer Ingelheim US
Click to read more on the Boehringer Ingelheim initiative to combat the rising incidence rates of heartworm disease in dogs by over half a million.
Boehringer Cares Patient Assistance Portal
Click here to find out more about Boehringer Ingelheim's Boehringer Cares patient assistance program portal.
Looking Ahead at Recruitment in the Biopharma Industry
Looking Ahead at Recruitment in the Biopharma Industry
Worldwide Partnering Contacts
Worldwide Partnering Contacts
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
New Documentary Highlights Ranch’s Commitment to Cattle Health
New Documentary Highlights Ranch’s Commitment to Cattle Health
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Fighting Rabies in Madagascar | Boehringer Ingelheim US
Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
New Swine Vaccine Combination Released | Boehringer Ingelheim US
Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.
Meeting the Challenge in Animal Health
Video showing how Boehringer Ingelheim Animal Health is driving collaboration and innovation to Meet the Challenge in Animal Health.
The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US
The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
Adopting shelter pets: Employees make a difference at work and home
Adopting shelter pets: Employees make a difference at work and home
Sunshine Act Compliance
Sunshine Act Compliance
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Yanina Donatini
Yanina Donatini, Head of ITM&S Content Production at Boehringer Ingelheim speaks about her 20 years in the company as innovative and diverse.